Iberis amara
Botanicalexperimental
Iberogast, also known as STW5, is a liquid formulation of nine herbs used for functional dyspepsia and irritable bowel syndrome. A proprietary blend, it was developed in Germany in 1961 and is available in other countries. Named after the genus (Iberis) of one of its ingredients, it is also claimed to possess anti-inflammatory, antioxidative and free radical–inhibiting properties as well as the ability to reduce gastric acid secretion. — Wikipedia
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jun 18, 2009 (NCT04059900)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIberogast ↗
Also known as
- iberogast
- iberogast
- stw 5 preparation
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02719496 | Phase 2 | Apr 1, 2016 | University of Nantes |
| NCT02660970 | N/A | Jan 1, 2016 | University of Bern |
| NCT02246686 | Phase 2 | Nov 1, 2014 | Bayer |
| NCT01940848 | Phase 3 | Oct 11, 2013 | Bayer |
| NCT04059900 | Phase 2 | Jun 18, 2009 | Bayer |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 3 | 3 | 2 | 2009 |
| University of Bern | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Nantes | Academic/Hospital | 1 | 1 | 1 | 2016 |
3 organizations
Page 1 / 1